Bipolar Resources – Myself

Overview

Bipolar disorder is associated with inherited differences in how the brain regulates mood, energy, sleep, activity and decision-making. You may experience depression, periods of unusually high energy or activity, and times when you feel relatively stable. Some people experience severe mania, others have shorter periods of hypomania, and for many people depression is the most persistent difficulty.

Bipolar disorder has a particularly strong genetic and biological foundation. Family and twin studies estimate heritability at approximately 60–80%. A major 2025 genomic study compared 158,036 people with bipolar disorder with approximately 2.8 million other participants, identifying 298 associated genomic regions and prioritising 36 genes. The findings implicate neuronal signalling and the activity of particular types of brain cells. Researchers also identified biological differences between bipolar I and bipolar II (O’Connell et al., Nature, 2025).

The biology is becoming increasingly tangible. Researchers can take cells donated by people with bipolar disorder, develop them into neurons in the laboratory and measure how those neurons transmit electrical signals. A 2024 study found unusually high neuronal activity and showed that lithium changed this activity differently in cells from people who responded well to lithium compared with cells from people who did not (Khayachi et al., eBioMedicine, 2024).

There are effective ways to improve the course of bipolar disorder. Medicines can treat episodes and reduce recurrence. Other interventions help you recognise early signs, manage depressive symptoms and improve functioning. Treatment can also help protect the things that episodes sometimes damage: relationships, work, finances and a sense of belonging.

This page covers symptoms, prognosis, relationships, work, sexuality and treatment, with more technical genomics and biological research in Learn more.

On this page: Early warning signs · How to get diagnosed? · Life trajectory · Things you might need to work on · Workplace success · Family dynamics · Friendship & social skills · Intimate relationships · Self-help & coping · How it can be for Them to interact with You · Learn more (the Science) · Organisations · Resources · Other people like you

Early warning signs

Bipolar patterns often first become noticeable during adolescence or early adulthood. The initial change may be a depressive episode rather than a period of high mood. Some people recognise the pattern quickly; others spend several years being treated for depression before an episode of hypomania or mania makes the broader picture clear.

An emerging period of high mood or activity can begin with changes that initially feel pleasant or productive:

• Needing less sleep. You may sleep four or five hours and still feel full of energy. This differs from insomnia, where you want to sleep but cannot and feel exhausted afterwards.
• Increasing mental and physical activity. You may begin several projects, work unusually long hours, exercise much more or feel compelled to keep moving.
• Faster thoughts and speech. Ideas arrive quickly, conversations move between topics and you may find interruptions unusually frustrating.
• Greater confidence or irritability. You may feel exceptionally capable, sociable, optimistic, impatient or certain about decisions that would normally deserve more thought.
• Changes in spending, sexuality or risk-taking. You may make unusually large purchases, take financial risks, pursue sexual encounters more impulsively or make major commitments very quickly.
• Increasing intensity. Friends or a partner may notice that your behaviour, pace or reactions are changing even if the experience still feels good to you.

An emerging depressive period may have a very different sequence: waking exhausted, sleeping longer or waking unusually early, finding ordinary tasks increasingly effortful, losing interest in activities, withdrawing from messages, thinking more slowly or becoming less hopeful about the future. Some people experience mixed features, when depressive feelings occur alongside agitation, racing thoughts, reduced sleep or high internal energy. Those periods can be particularly distressing.

Sleep and activity are useful biological signals. In a 2025 prospective study, 164 people with bipolar disorder were monitored using wearable devices. Changes in sleep-stage patterns and daily activity helped identify the onset of hypomanic episodes, often over a matter of days (Ortiz et al., Journal of Affective Disorders, 2025).

Start by identifying your own first three changes. They might be waking at 4 a.m. without feeling tired, writing unusually long messages and starting new projects. During depression, the earliest change might be losing interest in music, missing appointments or avoiding friends.

A brief daily record of sleep, energy and activity may reveal a recurring pattern before an episode becomes obvious.

If you are sleeping very little while becoming increasingly activated, experiencing psychosis, making decisions that create immediate danger, or feeling unable to stay safe during depression, arrange urgent clinical assessment. If you have thoughts of suicide or immediate danger, use local emergency services or an available crisis service. These are symptoms and situations that deserve timely, effective care.

How to get diagnosed?

What are the symptoms of bipolar disorder? The defining feature is the occurrence of distinct episodes in which mood and energy or activity change significantly from your usual state. A clinician evaluates the symptoms, how long they last, their effects on your life and what happens between episodes.

Mania

Mania involves a sustained period of unusually elevated, expansive or irritable mood and increased energy or activity. A recognised manic episode typically lasts at least one week, or a shorter period if hospital care is required because of its severity. Other characteristic symptoms include:

• Needing substantially less sleep while remaining energetic.
• Speaking much more or much faster than usual.
• Thoughts racing or moving quickly between ideas.
• Being easily distracted or unusually restless.
• Feeling much more confident, powerful or capable than is typical for you.
• Intensely pursuing goals, projects, social activity or work.
• Making unusually impulsive decisions involving money, sex, travel, substances or other significant consequences.

Mania can seriously disrupt judgement and everyday functioning. Some people also experience psychosis, including firmly held beliefs that do not correspond to reality or perceptions that others do not share.

Hypomania

Hypomania involves a similar change in mood and energy but is less severe. Under commonly used diagnostic criteria, the episode lasts at least four consecutive days and is noticeably different from the person’s usual functioning. Other people may observe the change, even when it feels especially enjoyable, productive or manageable to the person experiencing it. Hypomania does not involve the severe impairment or psychosis that characterises mania.

Depression

A major depressive episode generally lasts at least two weeks and involves persistent low mood or markedly reduced interest or pleasure, accompanied by changes such as exhaustion, impaired concentration, altered sleep or appetite, slowed activity, feelings of hopelessness or suicidal thinking. Bipolar depression can be physically and cognitively disabling, including for people whose hypomanic episodes are comparatively brief.

Bipolar I is diagnosed when someone has experienced at least one manic episode. Depressive episodes are common but are not required for the formal diagnosis. Bipolar II involves at least one hypomanic episode and at least one major depressive episode, without a history of full mania. There are also cyclothymic and other bipolar-spectrum presentations involving different patterns of elevated and depressive symptoms. Bipolar II is not necessarily a less consequential condition: depression may be frequent and prolonged (Berk et al., World Psychiatry, 2025).

Mixed features mean that symptoms associated with depression and elevated mood occur together or overlap during an episode. For example, you may feel deeply depressed while experiencing racing thoughts, agitation, increased energy or difficulty sleeping. This matters for choosing treatment and assessing immediate safety.

Diagnosis usually comes from a detailed clinical history rather than a single appointment or questionnaire. A clinician should ask about your strongest periods of depression and your most activated periods, including changes in sleep, confidence, spending, sexuality, speech, behaviour and everyday functioning. Information from someone who knows you well can be useful if you wish to involve them. Blood tests may help identify physical conditions such as thyroid disease that can mimic or contribute to mood symptoms, but there is currently no clinically validated genetic test, blood panel or scan that diagnoses bipolar disorder in one individual.

It is important to distinguish episodes lasting days or weeks from shorter emotional changes. Bipolar symptoms can overlap with ADHD, BPD, schizophrenia-spectrum conditions, substance use or physical illnesses; some people have more than one condition. A sustained change from your usual sleep, activity and judgement helps distinguish these patterns.

The diagnostic process can take time. A 2022 Canadian study reported a median delay of five years for bipolar I and eleven years for bipolar II in its clinical sample, partly because depression is often recognised before hypomania (Keramatian et al., Journal of Affective Disorders, 2022). If you are seeking an assessment, examples from both high-energy and depressive periods, with approximate dates and durations, can be more useful than an isolated mood score.

Life trajectory

Bipolar disorder usually involves a continuing biological susceptibility, but its effects can change substantially over a lifetime. Many people achieve long periods of stable mood and better functioning, especially when recurrent episodes are recognised and effectively treated. The frequency, severity and balance of depressive and elevated episodes differ greatly between people.

An episode ending does not necessarily mean life has returned to normal. Symptomatic recovery is improvement in episode symptoms; sustained remission means those gains continue. Functional recovery means regaining work, relationships and everyday functioning. These often happen at different rates.

Research following people after their first manic episode found that recovery from the acute episode was common, while recurrent episodes and continuing functional difficulties were also common. More recent research on bipolar II depression similarly found that improvements in depressive symptoms were more frequent than full recovery in everyday functioning (Journal of Affective Disorders, 2026).

Recurrence is a real part of the prognosis. Even with medication, many people experience further episodes over the following years. This is why long-term management focuses on reducing both the probability and the consequences of recurrence. In a 2024 randomised study of 305 people who were initially in a stable phase, around 46–49% experienced another mood episode during follow-up while receiving one of two structured psychological treatments in addition to ongoing care. The trial compared two therapies, not therapy against no treatment (Hautzinger and the A2 BipoLife Consortium, JAMA Psychiatry, 2024).

Does bipolar disorder affect life expectancy? Yes. A systematic review involving data from more than 96,000 people estimated an average of approximately 13 potential years of life lost, although estimates varied substantially between populations and methods (Chan et al., British Journal of Psychiatry, 2022).

A Finnish population study followed 47,018 people with bipolar disorder. Compared with the wider population, deaths from external causes, including suicide and accidents, were approximately six times more frequent, while deaths from physical illnesses were approximately twice as frequent. Alcohol-related deaths and physical conditions both contributed to premature mortality (Paljärvi et al., BMJ Mental Health, 2023). These are group-level risks, not a prediction of your own lifespan.

Reducing that gap requires attention to mood episodes and physical health. Cardiovascular risk, blood pressure, weight, diabetes, kidney and thyroid function, medication effects, alcohol and other substances, and suicidal symptoms all warrant appropriate care. The point is to improve outcomes that genuinely change the course of a person’s life.

Your goals may include satisfying work, intimacy, stable finances, parenthood or years without a severe episode. If symptoms are controlled but exhaustion or damaged relationships remain, those concerns deserve attention in their own right.

Things you might need to work on

Your priorities depend on your episode pattern. Managing depression may be your main task, while someone else may need to concentrate on preventing mania.

• Recognising early signs. Identify changes in sleep, speech, social contact or decision-making that preceded previous episodes.
• Protecting recovery time. If sleep is shrinking and activity escalating, consider reducing commitments. During depression, manageable activity and contact may help prevent prolonged withdrawal.
• Managing major decisions. Consider delaying substantial spending, resignations or relationship commitments during a sharp change in mood and energy.
• Understanding medication response. Track benefits and effects on concentration, movement, weight, sleep and sex. Preventing mania while leaving significant depression or sedation may warrant review.
• Finding a daily rhythm. Notice whether shift work, overnight travel or consecutive late nights have preceded episodes.
• Addressing persistent depression. Consider appropriate psychological treatment, manageable activities, social contact and medication review, even if mania has been absent for years.
• Protecting relationships. Agree while stable how someone you trust can flag a familiar pattern and what response would help.

A one-page record of my early signs; what helps; when I want additional help can turn what you have learned from past episodes into something useful for the next one.

Workplace success

Bipolar disorder can substantially affect employment. Depression can impair concentration and energy. Hypomania may initially increase productivity, but escalation can bring overcommitment, conflict and disruption. Medication-related sedation or cognitive slowing can affect work between episodes.

There are meaningful population figures. A Swedish register study found that 45% of people with bipolar disorder were employed three years before their first recorded diagnosis, compared with 34% five years afterwards. Employment varied with educational opportunities, physical and mental health, other conditions and previous hospital care. These figures describe that study population and its labour market, not the percentage of people with bipolar disorder who are capable of working (Holm et al., Acta Psychiatrica Scandinavica, 2021).

Effective treatment can make a measurable difference to working life. A 2024 Finnish register study followed more than 50,000 people with bipolar disorder. During employed periods, mood-stabilising medication use was associated with a lower risk of prolonged sickness absence compared with periods without those medicines. The investigators compared different treatment periods within individuals, although the observational design cannot eliminate every alternative explanation (Holm et al., World Psychiatry, 2024).

Practical approaches include:

• Sleep-friendly hours. Predictable schedules and fewer overnight shifts if sleep disruption has preceded episodes.
• Realistic workloads. Avoid commitments that depend on sustaining an elevated period of productivity.
• Reviewing important decisions. Delay large spending, resignations or consequential public communications if you recognise an emerging episode.
• Concentration support. Written priorities, fewer simultaneous tasks and breaks during recovery or medication-related cognitive effects.
• Returning to work. A gradual return after an episode may be more sustainable than an immediate full workload.
• Privacy. You may be able to request adjustments without sharing your full medical history; legal protections vary.

Recent genetics research adds a further insight. In a 2024 study combining 4,782 genotyped people with bipolar disorder with long-term Swedish register data, genetic profiles associated with hospital admissions differed from those associated with unemployment and long-term sickness absence. This suggests that preventing severe mood episodes and improving occupational functioning are related but distinct treatment goals (Jonsson et al., American Journal of Psychiatry, 2024).

What matters is finding conditions that let you do satisfying work consistently and still have the energy for life outside it.

Family dynamics

Bipolar disorder often occurs in families because of its inherited component. Relatives may have bipolar I, bipolar II, recurrent depression or overlapping conditions, but not necessarily the same episode pattern.

Explain to people close to you what your episodes look like. During depression, you might need practical help or quiet company; during emerging mania, a direct observation about sleep or escalating activity. Agree on what would help while you are stable.

Be specific about help: attending an appointment together, covering a time-sensitive task or reviewing shared spending. Also consider what an episode has cost the household. Rebuilding trust after a painful argument, unexpected debt or weeks of unavailability may take longer than the mood episode itself.

Parenthood and pregnancy deserve particular attention. Bipolar disorder can be managed while raising children, but pregnancy, childbirth and the disruption of sleep after a baby arrives can affect the course of the condition. A 2024 meta-analysis estimated postpartum mood-episode recurrence at approximately 39% among women with bipolar disorder, with considerable variation between studies (Bipolar Disorders, 2024).

If you are considering pregnancy, review medication safety and relapse prevention before making changes. Some effective bipolar medicines have significant reproductive risks. In particular, valproate can cause serious fetal harm and is subject to strict restrictions in many countries. A plan may include specialist medication review, sleep arrangements after delivery and practical support from a partner, relatives or friends. Stopping an effective medicine abruptly can itself create serious risk (CANMAT perinatal guideline, Canadian Journal of Psychiatry, 2025).

If you have children, age-appropriate explanations and shared caregiving arrangements can help maintain stable routines during an episode. Children may need time and honest answers afterwards, especially if something upsetting happened.

Friendship & social skills

Social isolation can be one of the most painful consequences of bipolar disorder. During depression, you may stop answering messages, cancel repeatedly or withdraw for months. You may also become irritable and say things that hurt people close to you. During hypomania or mania, you might talk over others, send overwhelming numbers of messages, become unusually intense, make accusations or say things with a certainty you would not have when stable. Friends may feel pushed away, exhausted or hurt. Some distance themselves; some friendships end.

Coming out of an episode can be especially difficult if you feel more like yourself again but discover that the people you want to see are no longer there. You may remember what happened clearly, only partly, or differently from how your friends experienced it. Losing friendships, trust and years of social life is a recurring theme in interviews with people who have bipolar disorder (Ponticiello et al., Frontiers in Psychiatry, 2024).

Some friendships can be repaired. Others cannot. When you feel stable enough, it may help to acknowledge the particular words or actions that caused hurt, listen to how the other person experienced them and explain what you are doing to reduce the chance of a repeat. An apology does not require a long account of your symptoms. Nor does it guarantee that the other person will want to resume contact. That can be a real loss to grieve.

For friendships you want to maintain, small, honest messages during a depressive period can help: “I’m finding it hard to talk at the moment, but I haven’t forgotten you.” If you know a trusted friend can recognise your early signs, a discreet, mutually agreed gesture may help you notice a change in your speech or behaviour before a social situation deteriorates.

When your circle has become smaller, rebuilding it may take time. Regular activities, one-to-one friendships and peer groups can create opportunities for new connections without requiring you to explain your entire history. Research on wellbeing in bipolar disorder identifies social relationships, belonging and self-management as important parts of living well, beyond symptom control (Jupille et al., International Journal of Qualitative Studies on Health and Well-being, 2023).

Intimate relationships

Bipolar episodes can affect sexual interest, emotional availability, shared finances, family plans and the practical balance of a relationship. Some changes are temporary; others, including medication-related sexual effects or persistent depression, may last longer. It helps to distinguish which aspects are changing rather than assuming every relationship difficulty has the same explanation.

During hypomania or mania, sexual desire may increase significantly. You might feel unusually attractive, adventurous or certain about a new connection. At the same time, your capacity to evaluate consequences, spending or relationship commitments may be changing. A useful individual safeguard is to avoid irreversible decisions about money, relationships or sex when you recognise that sleep and activity have shifted sharply from your usual pattern.

During depression, sexual interest may decline, physical touch may feel tiring, or you may want closeness without sex. A partner may experience the same period differently. Try to explain what you want in ordinary language: more affection, time together, less pressure, privacy or a pause in sexual activity. Consent, comfort and mutual interest matter throughout a relationship. Severe mania, psychosis or intoxication can compromise the ability to make informed decisions; intimacy should wait until both people can freely participate.

Sexual side effects of medication are worth discussing. Some antipsychotic medicines can reduce libido, affect arousal or orgasm, and change hormone levels. Other medicines may affect energy, weight or sexual confidence. A 2025 study of 80 people with bipolar disorder in remission reported sexual dysfunction in 55% of participants and an association with relationship adjustment. This was one clinical sample, not a population-wide rate, but it shows why sexual health belongs in treatment reviews (Yazar and İzci, Frontiers in Psychiatry, 2025).

Another 2025 study directly examined relationship and sexual satisfaction among people with bipolar disorder and their partners, highlighting the importance of asking both people about their experience rather than treating the partner’s perspective as an afterthought (Andreasen et al., Sexual Medicine, 2025).

If your desire has changed markedly after beginning medication, ask your prescriber whether the medicine, dose, hormone effects, depression or another health issue could be involved. There may be alternatives, but changes should be planned around the risk of mood recurrence.

Episodes can also leave lasting damage to a partnership. Hurtful words, accusations, financial decisions or sexual encounters during mania may alter trust long after your mood has stabilised. You can acknowledge the consequences, work on preventing further episodes and rebuild closeness together if both of you want that. Sometimes a relationship does not recover. A separation may be painful even when it is the right decision for one or both people.

Practical agreements can help: how to discuss an emerging episode, which financial decisions to review together and what to do if someone becomes unwell. During stable periods, make room for affection, sex and ordinary shared activities that have nothing to do with managing bipolar symptoms.

Self-help & coping

Effective treatments address different problems: acute mania, bipolar depression and prevention of recurrence. Their benefits and trade-offs vary.

Treatments with established clinical benefit

Lithium. Strong evidence supports long-term prevention of mood episodes, particularly recurrent mania, although responses differ. Safe use requires blood-level monitoring, kidney and thyroid checks, and awareness of dehydration and drug interactions. A 2025 population study found higher rates of hypothyroidism and moderate kidney impairment than with alternatives (Chan et al., JAMA Network Open, 2025).

Other mood-stabilising medicines. Lamotrigine helps prevent depressive recurrence but does not rapidly treat acute mania. A 2024 meta-analysis found fewer recurrences than with placebo; gradual dose increases are needed because serious skin reactions are possible (Bipolar Disorders, 2024). Valproate and carbamazepine have different antimanic and maintenance roles; valproate has major reproductive restrictions.

Medicines with antimanic or antidepressant effects. Quetiapine, aripiprazole, olanzapine, lurasidone, cariprazine and others have evidence for particular phases of bipolar disorder; they are not interchangeable. Effects on sedation, weight, metabolism, movement, concentration, hormones and sexuality vary. Review whether each medicine achieves its intended purpose (CANMAT/ISBD treatment update, Focus, 2023).

Skills-based psychological treatment. Structured psychoeducation, cognitive behavioural therapy (CBT), family-focused approaches and interpersonal and social rhythm therapy (IPSRT) can improve relapse prevention and functioning, usually alongside medical treatment. They teach recognition of early signs, ways to address depressive thinking, and regulation of sleep and activity. A meta-analysis of 39 randomised trials found lower recurrence with structured adjunctive interventions than usual care (Miklowitz et al., JAMA Psychiatry, 2021).

Sleep and circadian-rhythm management. The timing of sleep and activity has a biological connection to episodes. IPSRT works directly with daily rhythms; if sleep disruption has repeatedly preceded episodes, adjusting your schedule can be an important part of treatment.

How to make treatment more personalised

Your own history is invaluable. Did a medicine prevent mania but leave depression? Did another improve mood yet make work difficult through sedation? Have changes in sleep, travel or substance use preceded episodes?

Track outcomes that matter: episodes, days missed from work, sleep, concentration, relationships and side effects. A treatment can work well for mania while doing too little for depression, functioning or physical health.

Genetics-based treatment selection is developing, especially for lithium response, but no test has been established that reliably tells an individual whether lithium will work. The much more immediate opportunity is to use clinical history, actual treatment response, physical measurements and your own measurable patterns systematically (Paribello et al., Pharmacogenomics, 2025).

Promising approaches with more limited or specific evidence

Bright-light therapy. Controlled trials and a 2025 international expert assessment support carefully supervised bright-light therapy as an additional treatment for bipolar depression. Light exposure changes circadian signalling, and timing and duration matter. Hypomanic symptoms can emerge, so it should be planned with a clinician familiar with bipolar disorder rather than used as an unsupervised high-intensity experiment (ISBD Chronobiology Task Force, Bipolar Disorders, 2025).

Ketamine for treatment-resistant bipolar depression. A 2026 randomised trial tested four intravenous infusions over two weeks in 68 people. Clinically meaningful depressive improvement occurred in 35.3% of people receiving ketamine compared with 11.8% receiving the comparison treatment. Benefits diminished after treatment stopped, and longer-term effectiveness and safety require further evaluation. This is a specialist option for selected circumstances, rather than a replacement for proven maintenance care (Orsini et al., JAMA Psychiatry, 2026).

Brain stimulation. Electroconvulsive therapy (ECT) has an established clinical role in some severe or treatment-resistant mood episodes. Newer approaches such as repetitive transcranial magnetic stimulation and personalised theta-burst protocols are under active investigation for bipolar depression. A 2025 sham-controlled pilot of accelerated, MRI-guided theta-burst stimulation showed encouraging changes in some participants, but included only 13 randomised patients and did not demonstrate a statistically significant difference between treatment groups (Appelbaum et al., JAMA Network Open, 2025).

Approaches that have been tested but have not shown convincing overall benefits

Antidepressants as a stand-alone approach. Bipolar depression requires an assessment of previous hypomania or mania and mixed symptoms. Antidepressants may be useful for selected people, often alongside mood-stabilising treatment, but taking one without addressing bipolar recurrence is not generally the preferred long-term strategy. A 2025 analysis of randomised trials found no statistically significant increase in manic switching for any individual antidepressant compared with placebo, although the certainty was low and evidence for monotherapy was limited. Decisions should therefore be individualised, not based on an assumption that every antidepressant inevitably triggers mania (eClinicalMedicine, 2025).

Meditation and mindfulness alone. Some people find these techniques useful for anxiety, concentration or depressive rumination. Trials have not established them as reliable stand-alone treatments for preventing bipolar episodes. If meditation helps you relax or notice a change in mood, that can be valuable without expecting it to replace mood-stabilising treatment.

Yoga, breathing programmes and exercise. Ordinary physical activity is useful for cardiovascular health, energy and wellbeing. A 2025 review found some evidence of improvement in depressive and anxiety symptoms with exercise interventions, but the trials were generally small and of limited methodological quality, and convincing effects on mania were not established. Specialised yoga or breathwork programmes should be assessed on the same evidence standard as any other treatment (Frontiers in Psychiatry, 2025).

Nutritional supplements and microbiome products. Small trials of omega-3 fatty acids have produced some encouraging results for bipolar depressive symptoms, but sample sizes have been limited and consistent prevention of relapse has not been established. A randomised study of a probiotic formulation in 131 people with bipolar or schizophrenia-spectrum conditions found improvements in some markers of gut health but no significant improvement in the primary psychiatric-symptom outcome (Schizophrenia Bulletin, 2025).

Commercial DNA and biomarker packages. A report describing inherited associations is different from a clinically validated test that improves treatment selection. If a company offers a genetic, inflammatory or hormone profile to determine your bipolar medication, ask what controlled study shows that using the test improves outcomes for people with bipolar disorder.

Build a practical individual plan

Choose the problems you most want to change. These may include recurrent mania, long periods of depression, disrupted sleep, missed working days, financial consequences, sexual side effects or difficulties resuming social life after an episode. Select two or three measurable outcomes and review them over time with the treatment team you choose.

If your symptoms change significantly, arrange a timely treatment review. Abruptly stopping lithium or other prescribed mood-stabilising medicines can increase the risk of recurrence and should be discussed with the prescriber. During severe depression, suicidal thinking or rapidly escalating mania, the priority is a prompt clinical response rather than relying on self-help techniques alone.

How it can be for Them to interact with You

The people around you may experience an episode very differently from you. A period of mania that feels exciting, urgent or absolutely clear to you might leave a partner worried about shared money, a colleague upset by something you said, or a friend overwhelmed by the intensity of contact. During depression, someone who cares about you may feel shut out or hurt by repeated withdrawal or harsh words. These effects can continue after the episode has ended.

Close friends or family may notice changes in your sleep, speech and pace early. You might agree that they speak plainly: “You’ve hardly slept for three nights, and you’re talking much faster. Are you feeling okay?” If you prefer something less conspicuous in company, agree on a discreet gesture that refers to a particular pattern you both recognise. It works best when you have chosen its meaning together, during a settled period.

After an episode, ask what the other person experienced. Their account may differ from your memory, but it can help you understand damaged trust, shared financial consequences or why they have become more distant. You can then discuss practical changes and boundaries without making every conversation about bipolar disorder.

People close to you also have needs and limits. Someone may care deeply about you and still be unable to continue a particular role or relationship. If an episode caused serious harm, recovery may involve grief as well as treatment. You can share reliable biological and clinical information with those who want to understand what happened, while recognising that information alone may not repair the hurt.

Learn more (the Science)

Genomic architecture and heritability. The 2025 multi-ancestry genome-wide association study combined data from 158,036 bipolar cases and 2,796,499 controls across 79 cohorts. It identified 337 independent significant variants mapping to 298 loci. Fine-mapping and gene-prioritisation methods implicated 36 genes, while differences between bipolar I and II and between clinically ascertained and self-reported cases revealed variation in genetic architecture. Associated variation was enriched in neuronal populations, including GABAergic interneurons and medium spiny neurons. The 60–80% heritability estimate comes from family and twin designs; the smaller proportion captured by common-variant analyses measures a different component of genetic susceptibility (O’Connell et al., Nature, 2025).

Ion channels and excitatory–inhibitory signalling. Several risk genes influence neuronal excitability, calcium-channel function, axonal development and synaptic transmission. A 2025 fine-mapping study prioritised variants and genes involving SCN2A, CACNA1B, TRANK1, SYNE1 and other candidates. SCN2A encodes a voltage-gated sodium-channel subunit that influences action potentials, while CACNA1B encodes a voltage-gated calcium-channel subunit important to neurotransmitter release. Inhibitory GABAergic cells regulate the timing and intensity of activity in interconnected neural circuits. These pathways provide concrete molecular targets for understanding the condition and developing new interventions (Nature Neuroscience, 2025).

Patient-derived neuronal models. Induced pluripotent stem cells (iPSCs) can be differentiated into neurons while retaining a donor’s inherited DNA sequence. Researchers compare firing rates, sodium currents, calcium transients, synaptic activity, transcriptomes and protein phosphorylation patterns. In a 2024 study, increased neuronal excitability was reversed by lithium in cultures derived from clinically lithium-responsive individuals, while neuronal cultures from non-responders showed a different response. Activation of AMP-activated protein kinase (AMPK) reduced network hyperactivity in both responder and non-responder models. This is a cellular experimental result; AMPK activators have not thereby been established as clinical bipolar treatments (Khayachi et al., eBioMedicine, 2024).

Synaptic proteins and lithium response. A 2025 study used bipolar patient-derived neurons to examine synapsin I (SYN1) and PSD-95, proteins involved in presynaptic vesicle function and postsynaptic organisation. Researchers observed differences in baseline expression and found that lithium increased PSD-95 selectively in neurons from people who had responded to it clinically. This offers a specific molecular hypothesis for differences in drug response and a potential direction for developing predictive assays. The result is preliminary and has not established a blood or cellular test for clinical prescribing (Rohr et al., Neuropharmacology, 2025).

Circadian phase as a measurable phenotype. Circadian regulation involves molecular clock genes, neuronal circuits, hormones such as melatonin and the timing of sleep, activity and light exposure. A 2024 prospective study of 168 people with mood disorders derived 36 sleep–circadian features from wearables and previous episode histories. The authors reported promising next-day prediction performance for depression, mania and hypomania, with circadian phase shifts among the strongest features. Delayed phase was associated with depressive episodes and advanced phase with manic episodes in the study. These results require external testing before use as a routine clinical prediction system (Lim et al., npj Digital Medicine, 2024).

Structural imaging and disease course. MRI studies examine cortical thickness, surface area, subcortical volumes and white-matter measures. In a longitudinal ENIGMA study involving 1,232 individuals, researchers found faster ventricular enlargement on average among people with bipolar disorder and an association between more manic or hypomanic episodes and greater frontal cortical thinning. They did not find globally accelerated cortical thinning across the entire bipolar group. This supports investigating relationships between episode burden and specific brain trajectories, without treating an MRI finding as an individual diagnostic signature (Biological Psychiatry, 2022).

Polygenic profiles and different life outcomes. A 2024 Swedish study connected genetic data from 4,782 people with bipolar disorder with at least a decade of information on employment, sick leave and hospital admissions. Genetic scores associated with bipolar disorder and schizophrenia related to admission burden, whereas occupational difficulties correlated more with scores for depression, ADHD, schizophrenia and educational attainment. The pattern suggests that different molecular liabilities may contribute to different aspects of functioning. It does not mean these scores can reliably predict one person’s job prospects (Jonsson et al., American Journal of Psychiatry, 2024).

Pharmacogenomics and multiomics. Research groups are combining genome-wide variation, transcriptomics, phosphoproteomics and clinical treatment-response data. A 2024 replication analysis linked lithium-response biology to focal adhesion and PI3K–Akt networks across independent datasets. A 2025 pathway-specific polygenic-score study identified associations involving GABA, calcium signalling, mitochondria, circadian pathways and glycogen synthase kinase (GSK), but the scores explained only a small proportion of variability in lithium response. These are biologically informative findings, with clinical prediction still requiring stronger independent validation (Translational Psychiatry, 2024; Biological Psychiatry Global Open Science, 2025).

What makes a biomarker clinically useful? A genomic association, a difference in neuronal firing or a characteristic of sleep is a reproducible scientific finding when demonstrated in appropriate studies. A clinical test also needs to answer a question reliably for an individual: Does it improve diagnosis? Does it predict recurrence early enough to change treatment? Does using it improve the choice of medicine or reduce side effects? These are the standards by which proposed precision-medicine services should be assessed. Current biological research is developing the necessary foundations; individualised care today can already make substantial use of episode history, clinical response, blood-level monitoring and physiological patterns.

Organisations

• Bipolar UK — peer support, mood-monitoring resources, self-management courses and workplace information.
• Bipolar Scotland — in-person and online groups, peer support, self-management training and employment-related programmes in Scotland.
• Depression and Bipolar Support Alliance (DBSA) — United States-based peer-led groups, education and practical resources on depression and bipolar conditions.
• International Society for Bipolar Disorders (ISBD) — scientific and patient-facing materials, including information about clinical approaches and international resources.
• CREST.BD — a collaborative research network involving people living with bipolar disorder, with an emphasis on quality of life and practical self-management.
• WHO QualityRights — international materials supporting autonomy, dignity and rights in healthcare.

The availability of groups and services varies between countries. Some organisations offer online material internationally even when direct support is primarily local.

Resources

These research papers and clinical resources provide more detail on the findings discussed throughout this page:

• Genomics: Multi-ancestry bipolar GWAS — Nature, 2025; fine-mapping of bipolar risk genes — Nature Neuroscience, 2025.
• Neuronal signalling and lithium: Patient-derived neurons and Akt/AMPK pathways — eBioMedicine, 2024; synaptic proteins and lithium response — Neuropharmacology, 2025; multiomics replication of lithium-response pathways — 2024.
• Sleep and early warning signs: Wearable monitoring before hypomania — 2025; sleep and circadian features for episode prediction — npj Digital Medicine, 2024.
• Long-term outlook and mortality: Life-expectancy meta-analysis — 2022; Finnish national mortality study — BMJ Mental Health, 2023; bipolar II course and prognosis — World Psychiatry, 2025.
• Work and functioning: National register study of work and medication — World Psychiatry, 2024; polygenic profiles and employment — American Journal of Psychiatry, 2024.
• Treatments that have been tested: CANMAT/ISBD evidence update — 2023; psychological-intervention trial — JAMA Psychiatry, 2024; bright-light therapy recommendations — 2025; ketamine trial — JAMA Psychiatry, 2026.
• Physical and reproductive health: Lithium, thyroid and kidney outcomes — 2025; perinatal clinical guideline — 2025; relationship and sexual satisfaction — 2025.
• Friendship, isolation and lived experience: Interviews on self-perception and relationships — Frontiers in Psychiatry, 2024; qualitative study of wellbeing and connectedness — 2023.

You can also explore Relatix Health’s condition resources and developments through Relatix Bio. If considering a research study or new treatment service, check the actual evidence, expected benefits, safety monitoring, costs and the availability of independent clinical review.

Other people like you

People describe bipolar disorder in different ways. Some remember a manic episode that rapidly changed their finances or relationships. Others have managed recurrent depression for years before recognising hypomania. Some find that lithium or another medicine brings sustained stability; others are still trying to prevent episodes without unacceptable side effects.

It can be particularly helpful to meet someone who understands what it is like to return from an episode to a friendship that has ended, or to feel too depressed to keep in touch. You may want to know how others rebuilt a social circle, returned to work, discussed sexuality with a partner or recognised changes before another episode.

Peer groups and lived-experience organisations can provide practical ideas and new connections. What helps will depend on your episode pattern, circumstances and preferences.

We would also like to learn from what you notice. Which early warning signs reliably predict an episode for you? Have changes to medication, sleep, work, activity or relationships improved how you feel and function? Which treatments were ineffective or came with unacceptable trade-offs? What outcomes would you most like researchers to measure?

The combination of strong genomic evidence, measurable biological functioning, effective treatment and individual experience is what makes a precision-medicine approach useful. There is already a great deal that can be done to improve the course of bipolar disorder, and the newest research is providing increasingly detailed ways to understand why different approaches work for different people.